VASOPRESSIN
Vasopressin (ADH/AVP) is a nonapeptide hormone synthesized in the hypothalamus and released by the posterior pituitary, crucial for fluid balance by increasing renal water reabsorption via V2 receptors. It also regulates blood pressure through V1 receptor-mediated vasoconstriction.
Vasopressin (arginine vasopressin/AVP) is a neuropeptide hormone produced in the hypothalamus that regulates water balance, blood pressure, and plays a crucial role in social behavior and cognition. Research indicates that cerebrospinal fluid (CSF) vasopressin concentration is a biomarker of social functioning, with low levels associated with autism spectrum disorder and social impairment in both children and primates.
Research
Reported Effects
Research Evidence:: Strong preclinical evidence in primate models showing improvements in social cognition and face recognition. Autism Applications:: Low CSF vasopressin levels strongly correlate with social impairment in ASD, suggesting replacement therapy potential. Administration Method:: Nebulized vasopressin successfully penetrates the CNS and increases CSF levels in animal models. Individual Variation:: May only be effective for specific subgroups (those with vasopressin deficiency, primarily males) rather than general population
- Strong preclinical evidence in primate models showing improvements in social cognition and face recognition
- Low CSF vasopressin levels strongly correlate with social impairment in ASD, suggesting replacement therapy potential
- Nebulized vasopressin successfully penetrates the CNS and increases CSF levels in animal models
- May only be effective for specific subgroups (those with vasopressin deficiency, primarily males) rather than general population
Safety Profile
Safety Profile: Vasopressin (Antidiuretic Hormone)
Common Side Effects
- Nausea, vomiting, and abdominal cramps
- Skin pallor and circumoral pallor
- Headache and dizziness
- Sweating and tremor
- Injection site reactions (IV/IM/SC administration)
- Mild hyponatremia (dilutional, from water retention)
Serious Adverse Effects
- Water intoxication and severe hyponatremia: Potentially fatal; results from excessive water retention with inadequate free water restriction
- Myocardial ischemia and infarction: Vasopressin causes coronary vasoconstriction; significant risk in patients with coronary artery disease
- Peripheral ischemia and gangrene: Potent vasoconstriction can compromise extremity perfusion, particularly at high doses or with extravasation
- Mesenteric ischemia: Can cause bowel ischemia, especially in shock states
- Cardiac arrhythmias: Including bradycardia and atrial fibrillation
- Severe hypertension
- Rhabdomyolysis from ischemia
- Skin necrosis with SC injection or IV extravasation
Contraindications
- Chronic nephritis with elevated blood nitrogen
- Coronary artery disease (relative contraindication; use only in life-threatening situations)
- Known hypersensitivity to vasopressin or its preservatives
- Vascular disease with compromised peripheral perfusion
Drug Interactions
- Carbamazepine, SSRIs, chlorpropamide, TCAs: Enhance antidiuretic effect; increased hyponatremia risk
- Lithium, demeclocycline: Reduce antidiuretic effect
- Norepinephrine and other vasopressors: Additive vasoconstriction; increased ischemia risk
- Ganglionic blocking agents: Enhanced vasopressor response
- Indomethacin: May potentiate antidiuretic effect
Population-Specific Considerations
- Septic shock: First-line vasopressor adjunct (per Surviving Sepsis guidelines) at 0.03–0.04 units/min
- Diabetes insipidus: Diagnostic and therapeutic use; desmopressin (DDAVP) preferred for chronic management (more selective V2 activity)
- Variceal bleeding: IV vasopressin used in GI hemorrhage; nitroglycerin co-infusion recommended to reduce cardiac ischemia
- Cardiac arrest: ACLS protocols have removed vasopressin as an alternative to epinephrine (2015 AHA guidelines)
- Pregnancy: Category C; may induce uterine contractions; use only when clearly needed
- Central line preferred: Peripheral IV administration carries significant extravasation injury risk
Pharmacokinetic Profile
Safety Profile
Common Side Effects
- Aggression Concerns:: May increase aggression in neurotypical individuals with intact vasopressin signaling, though not observed in low-social subjects
- Individual Response:: One user reported it wasn't particularly helpful 20 years ago, suggesting variable individual responses
- Limited Data:: Minimal user-reported side effects due to very limited availability and usage
- Market Removal:: Historical removal from Scandinavian markets suggests potential safety or efficacy concerns
References (4)
- [2]Nebulized vasopressin penetrates CSF and improves social functioning in low-social monkeys
→ Nebulized vasopressin administration improved face recognition and prosocial responses to affiliative communication cues in low-social rhesus monkeys without inducing aggression, with vasopressin levels increasing in CSF following administration.
- [1]Cerebrospinal Fluid Vasopressin Concentration Is a Biomarker of Autistic Social Impairment and Hypothalamic Vasopressin Gene Expression in Humans
→ Study found that CSF vasopressin concentration serves as a biomarker for social impairment in autism, with low levels predicting autistic traits and social difficulties in both children and adults.
- [3]Vasopressin as Possible Treatment Option in Autism Spectrum Disorder
→ Review suggests vasopressin may contribute to multiple ASD symptoms including social skills, communication, motor function, and sleep disturbances, with potential as a targeted treatment though likely only beneficial for certain subgroups.
- [4]Neonatal CSF vasopressin concentration predicts later medical record diagnoses of autism spectrum disorder
→ Neonatal CSF AVP concentrations were significantly lower among ASD cases than controls and individually predicted case status, suggesting a neurochemical marker of ASD may be present very early in life.